Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347381 | 0.84 | LMNA (0.35) | LMNACA12CA1CA2CA3 | |
| SCHEMBL346137 | 0.74 | HTR2A (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL345522 | 0.71 | CCR2 (0.39) | LMNACCR2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL346818 | 0.68 | HTR2A (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11286560 | 0.67 | BRPF1 (0.50) | MAPTCA12CA9ALDH1A1KDM4E | |
| SCHEMBL27830151 | 0.63 | POLB (0.49) | MAPTLMNACA12CA1CA2 | |
| SCHEMBL1314608 | 0.63 | GRM2 (0.40) | MAPTLMNACA12CA1CA2 | |
| SCHEMBL1311939 | 0.63 | GRM2 (0.40) | MAPTLMNACA12CA1CA2 | |
| SCHEMBL2632950 | 0.62 | HTR2A (0.45) | BACE1SLC6A2SLC6A4ALDH1A1KDM4E | |
| SCHEMBL2012127 | 0.61 | NPY5R (0.44) | MAPTLMNABACE1CCR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-01-19 | — | — | US | claimed |
| EP-2387562-A1 | Quinolinone derivatives useful for the treatment of cns disorders | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| WO-2010081900-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-01-19 | — | — | US | disclosed |
| EP-2387562-A1 | Quinolinone derivatives useful for the treatment of cns disorders | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | disclosed |
| WO-2010081900-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | AQP4, PMP22, CHRNA2 | MAPT 153/4885LMNA 3197/4885CA12 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.